CSPC Pharmaceutical Group Limited — Board/Management Information 2014

Mar 19, 2014

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [410 x 87] intentionally omitted <==

==> picture [410 x 86] intentionally omitted <==

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND RULE 3.10A OF THE LISTING RULES

Resignation of independent non-executive director

The Board hereby announces that Mr. Guo Shichang resigned as independent non-executive director of the Company with effect from 19 March 2014 due to retirement.

Compliance with rule 3.10A of the Listing Rules

Following the resignation of Mr. Guo, the number of independent non-executive directors on the Board represents less than one-third of the members of the Board as required under rule 3.10A of the Listing Rules.

The Company is endeavoring to identify a suitable candidate to act as an independent non-executive director to meet the requirement set out in rule 3.10A of the Listing Rules as soon as practicable and will make further announcements as and when appropriate.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board of Directors (the “Board”) of CSPC Pharmaceutical Group Limited (the Company”) hereby announces that Mr. Guo Shichang resigned as independent non-executive director of the Company with effect from 19 March 2014 due to retirement.

Mr. Guo Shichang has confirmed that he has no disagreement with the Board and there are no other matters that need to be brought to the attention of the shareholders of the Company in relation to his resignation as independent non-executive director of the Company.

The Board would like to take this opportunity to express its gratitude to Mr. Guo Shichang for his valuable contribution to the Company in the past years.

COMPLIANCE WITH RULE 3.10A OF THE LISTING RULES

According to rule 3.10A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”), the Company is required to appoint independent non-executive directors representing at least one-third of the members of the Board.

Following the resignation of Mr. Guo, the composition of the Board comprises ten (10) executive directors, one (1) non-executive director and five (5) independent non-executive directors. The number of independent non-executive directors on the Board represents less than one-third of the members of the Board as required under rule 3.10A of the Listing Rules.

1 -

The Company is endeavoring to identify a suitable candidate to act as an independent non-executive director to meet the requirement set out in rule 3.10A of the Listing Rules as soon as practicable and will make further announcements as and when appropriate.

By Order of the Board CSPC Pharmaceutical Group Limited CAI Dongchen Chairman

Hong Kong, 19 March 2014

As at the date of this announcement, the Board comprises Mr. Cai Dongchen, Mr. Feng Zhenying, Mr. Chak Kin Man, Mr. Pan Weidong, Mr. Zhao John Huan, Mr. Wang Shunlong, Mr. Wang Huaiyu, Mr. Lu Jianmin, Mr. Wang Zhenguo and Mr. Wang Jinxu as executive Directors; Mr. Lee Ka Sze, Carmelo as non-executive Director and Mr. Huo Zhenxing, Mr. Qi Moujia, Mr. Chan Siu Keung, Leonard, Mr. Wang Bo and Mr. Zhang Fawang as independent non-executive Directors.

• 2 -